Chemed Reports First-Quarter 2017 Results
Consolidated operating results:
-
Revenue increased 4.0% to
$406 million -
GAAP Diluted EPS increased 22.8% to
$1.78 -
Adjusted Diluted EPS increased 12.3% to
$1.82
VITAS segment operating results:
-
Net Patient Revenue of
$282 million , an increase of 1.7% - Average Daily Census (ADC) of 16,222, an increase of 3.6%
- Admissions of 17,563, an increase of 4.1%
-
Net Income, including discrete items, of
$20.6 million , an increase of 7.9% -
Adjusted EBITDA of
$38.4 million , an increase of 7.0%
Roto-Rooter segment operating results:
-
Revenue of
$124 million , an increase of 9.5% -
Net Income of
$14.6 million , an increase of 12.3% -
Adjusted EBITDA of
$26.3 million , an increase of 12.7% - Adjusted EBITDA margin of 21.3%, an increase of 61 basis points
VITAS
Net revenue for VITAS was
In the first quarter of 2017, VITAS had a 26.1/73.9 RHC Days-of-Care
ratio and generated approximately
VITAS did not have any adjustments to revenue related to the
At
Of VITAS’ 31 unique
Average revenue per patient per day in the quarter was
The first quarter of 2017 gross margin was 21.5%, which is a 49 basis point improvement when compared to the first quarter of 2016.
Selling, general and administrative expense was
Roto-Rooter
Roto-Rooter’s plumbing and drain cleaning business generated sales of
Roto-Rooter’s gross margin in the quarter was 48.6%, a 106 basis point
improvement when compared to the first quarter of 2016. Adjusted EBITDA
in the first quarter of 2017 totaled
Chemed Consolidated
As of
In
Capital expenditures through
During the quarter, the Company repurchased 300,000 shares of
Guidance for 2017
Revenue growth for VITAS in 2017, prior to Medicare Cap, is estimated to
be in the range of 4% to 5%. Admissions and Average Daily Census in 2017
are estimated to expand approximately 3% to 4% and full-year Adjusted
EBITDA margin, prior to Medicare Cap, is estimated to be 14.5% to 15.0%.
We are currently estimating
Roto-Rooter is forecasted to achieve full-year 2017 revenue growth of 3% to 4%. This revenue estimate is based upon increased job pricing of approximately 2% and continued growth in water restoration services. Adjusted EBITDA margin for 2017 is estimated in the range of 21.5% to 22.0%.
Based upon the above, full-year 2017 adjusted earnings per diluted
share, excluding non-cash expense for stock options, costs related to
litigation, and other discrete items, is estimated to be in the range of
Conference Call
A taped replay of the conference call will be available beginning approximately 24 hours after the call's conclusion. It can be accessed by dialing (855) 859-2056 for U.S. and Canadian callers and +1 (404) 537-3406 for international callers and will be available for one week following the live call. The replay Conference ID is 98225002. An archived webcast will also be available at www.chemed.com.
This press release contains information about Chemed’s EBITDA, Adjusted
EBITDA and Adjusted Diluted EPS, which are not measures derived in
accordance with GAAP and which exclude components that are important to
understanding Chemed’s financial performance. In reporting its operating
results,
Forward-Looking Statements
Certain statements contained in this press release and the accompanying
tables are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. The words "believe,"
"expect," "hope," "anticipate," "plan" and similar expressions identify
forward-looking statements, which speak only as of the date the
statement was made.
These risks and uncertainties arise from, among other things, possible
changes in regulations governing the hospice care or plumbing and drain
cleaning industries; periodic changes in reimbursement levels and
procedures under
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | |||||||||||
CONSOLIDATED STATEMENT OF INCOME | |||||||||||
(in thousands, except per share data)(unaudited) | |||||||||||
Three Months Ended March 31, | |||||||||||
2017 | 2016 | ||||||||||
Service revenues and sales | $ | 405,864 | $ | 390,389 | |||||||
Cost of services provided and goods sold | 285,140 | 278,435 | |||||||||
Selling, general and administrative expenses (aa) | 69,458 | 59,045 | |||||||||
Depreciation | 8,893 | 8,424 | |||||||||
Amortization | 46 | 92 | |||||||||
Other operating expenses | 873 | - | |||||||||
Total costs and expenses | 364,410 | 345,996 | |||||||||
Income from operations | 41,454 | 44,393 | |||||||||
Interest expense | (995 | ) | (842 | ) | |||||||
Other income--net (bb) | 2,463 | (2,924 | ) | ||||||||
Income before income taxes | 42,922 | 40,627 | |||||||||
Income taxes | (13,078 | ) | (15,787 | ) | |||||||
Net income | $ | 29,844 | $ | 24,840 | |||||||
Earnings Per Share | |||||||||||
Net income | $ | 1.84 | $ | 1.49 | |||||||
Average number of shares outstanding | 16,219 | 16,720 | |||||||||
Diluted Earnings Per Share | |||||||||||
Net income | $ | 1.78 | $ | 1.45 | |||||||
Average number of shares outstanding | 16,801 | 17,170 | |||||||||
(aa) | Selling, general and administrative ("SG&A") expenses comprise (in thousands): | ||||||||||
Three Months Ended March 31, | |||||||||||
2017 | 2016 | ||||||||||
SG&A expenses before long-term incentive compensation, expenses | |||||||||||
related to the O.I.G. investigation and the impact of market value | |||||||||||
adjustments related to deferred compensation trusts |
$ | 63,732 | $ | 59,937 | |||||||
Market value gains/(losses) related to deferred compensation trusts | 2,615 | (2,987 | ) | ||||||||
Expenses related to O.I.G. investigation | 2,150 | 2,336 | |||||||||
Long-term incentive compensation | 961 | (241 | ) | ||||||||
Total SG&A expenses | $ | 69,458 | $ | 59,045 | |||||||
(bb) | Other income--net comprises (in thousands): | ||||||||||
Three Months Ended March 31, | |||||||||||
2017 | 2016 | ||||||||||
Market value gains/(losses) related to deferred compensation trusts | $ |
2,615 |
$ | (2,987 | ) | ||||||
Interest income |
85 |
97 | |||||||||
Loss on disposal of property and equipment | (236 |
) |
(33 | ) | |||||||
Other |
(1 |
) |
(1 | ) | |||||||
Total other income--net | $ | 2,463 | $ | (2,924 | ) | ||||||
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | ||||||||||||
CONSOLIDATED BALANCE SHEET | ||||||||||||
(in thousands, except per share data)(unaudited) | ||||||||||||
March 31, | ||||||||||||
2017 | 2016 | |||||||||||
Assets | ||||||||||||
Current assets | ||||||||||||
Cash and cash equivalents | $ | 47,049 | $ | 15,235 | ||||||||
Accounts receivable less allowances | 109,726 | 143,040 | ||||||||||
Inventories | 5,433 | 6,102 | ||||||||||
Prepaid income taxes | 1,663 | 3,258 | ||||||||||
Prepaid expenses | 12,102 | 12,306 | ||||||||||
Total current assets | 175,973 | 179,941 | ||||||||||
Investments of deferred compensation plans held in trust | 56,596 | 49,195 | ||||||||||
Properties and equipment, at cost less accumulated depreciation | 119,394 | 119,331 | ||||||||||
Identifiable intangible assets less accumulated amortization | 54,976 | 55,018 | ||||||||||
Goodwill | 472,391 | 472,438 | ||||||||||
Other assets | 6,901 | 6,996 | ||||||||||
Total Assets | $ | 886,231 | $ | 882,919 | ||||||||
Liabilities | ||||||||||||
Current liabilities | ||||||||||||
Accounts payable | $ | 29,341 | $ | 50,721 | ||||||||
Current portion of long-term debt | 9,375 | 18,000 | ||||||||||
Income taxes | 12,614 | 11,129 | ||||||||||
Accrued insurance | 54,150 | 45,628 | ||||||||||
Accrued compensation | 37,382 | 43,844 | ||||||||||
Accrued legal | 2,471 | 2,819 | ||||||||||
Other current liabilities | 19,050 | 19,416 | ||||||||||
Total current liabilities | 164,383 | 191,557 | ||||||||||
Deferred income taxes | 11,875 | 16,861 | ||||||||||
Long-term debt | 137,500 | 126,875 | ||||||||||
Deferred compensation liabilities | 56,024 | 49,188 | ||||||||||
Other liabilities | 15,805 | 13,617 | ||||||||||
Total Liabilities | 385,587 | 398,098 | ||||||||||
Stockholders' Equity | ||||||||||||
Capital stock | 34,404 | 34,076 | ||||||||||
Paid-in capital | 651,269 | 610,219 | ||||||||||
Retained earnings | 983,742 | 886,604 | ||||||||||
Treasury stock, at cost | (1,170,933 | ) | (1,048,509 | ) | ||||||||
Deferred compensation payable in Company stock | 2,162 | 2,431 | ||||||||||
Total Stockholders' Equity | 500,644 | 484,821 | ||||||||||
Total Liabilities and Stockholders' Equity | $ | 886,231 | $ | 882,919 | ||||||||
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | ||||||||||||||||||
CONSOLIDATED STATEMENT OF CASH FLOWS | ||||||||||||||||||
(in thousands)(unaudited) | ||||||||||||||||||
Three Months Ended | ||||||||||||||||||
March 31, | ||||||||||||||||||
2017 | 2016 | |||||||||||||||||
Cash Flows from Operating Activities | ||||||||||||||||||
Net income | $ | 29,844 | $ | 24,840 | ||||||||||||||
Adjustments to reconcile net income to net cash provided | ||||||||||||||||||
by operating activities: | ||||||||||||||||||
Depreciation and amortization | 8,939 | 8,516 | ||||||||||||||||
Provision for uncollectible accounts receivable | 4,249 | 4,242 | ||||||||||||||||
Stock option expense | 3,001 | 2,563 | ||||||||||||||||
Benefit for deferred income taxes | (2,415 | ) | (4,202 | ) | ||||||||||||||
Noncash long-term incentive compensation | 827 | (305 | ) | |||||||||||||||
Amortization of restricted stock awards | 336 | 539 | ||||||||||||||||
Amortization of debt issuance costs | 129 | 130 | ||||||||||||||||
Changes in operating assets and liabilities | ||||||||||||||||||
Decrease/(increase) in accounts receivable | 17,972 | (41,050 | ) | |||||||||||||||
Decrease in inventories | 322 | 212 | ||||||||||||||||
Decrease in prepaid expenses | 1,003 | 546 | ||||||||||||||||
Decrease in accounts payable and other current liabilities | (10,766 | ) | (7,567 | ) | ||||||||||||||
Increase in income taxes | 14,655 | 19,448 | ||||||||||||||||
Increase/(decrease) in other assets | (2,140 | ) | 410 | |||||||||||||||
Increase/(decrease) in other liabilities | 1,992 | (140 | ) | |||||||||||||||
Excess tax benefit on share-based compensation | - | (900 | ) | |||||||||||||||
Other sources/(uses) | 838 | (59 | ) | |||||||||||||||
Net cash provided by operating activities | 68,786 | 7,223 | ||||||||||||||||
Cash Flows from Investing Activities | ||||||||||||||||||
Capital expenditures | (9,020 | ) | (11,473 | ) | ||||||||||||||
Other sources/(uses) | (70 | ) | 153 | |||||||||||||||
Net cash used by investing activities | (9,090 | ) | (11,320 | ) | ||||||||||||||
Cash Flows from Financing Activities | ||||||||||||||||||
Proceeds from revolving line of credit | 116,000 | 59,000 | ||||||||||||||||
Payments on revolving line of credit | (76,000 | ) | (3,500 | ) | ||||||||||||||
Purchase of treasury stock | (54,262 | ) | (52,460 | ) | ||||||||||||||
Change in cash overdrafts payable | (8,607 | ) | 7,061 | |||||||||||||||
Proceeds from exercise of stock options | 5,635 | 2,887 | ||||||||||||||||
Dividends paid | (4,251 | ) | (4,081 | ) | ||||||||||||||
Capital stock surrendered to pay taxes on stock-based compensation | (4,744 | ) | (4,020 | ) | ||||||||||||||
Payments on other long-term debt | (1,875 | ) | (1,875 | ) | ||||||||||||||
Excess tax benefit on share-based compensation | - | 900 | ||||||||||||||||
Other sources | 147 | 693 | ||||||||||||||||
Net cash (used)/provided by financing activities | (27,957 | ) | 4,605 | |||||||||||||||
Increase in Cash and Cash Equivalents | 31,739 | 508 | ||||||||||||||||
Cash and cash equivalents at beginning of year | 15,310 | 14,727 | ||||||||||||||||
Cash and cash equivalents at end of period | $ | 47,049 | $ | 15,235 | ||||||||||||||
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | |||||||||||||||||
CONSOLIDATING STATEMENT OF INCOME | |||||||||||||||||
FOR THE THREE MONTHS ENDED MARCH 31, 2017 AND 2016 | |||||||||||||||||
(in thousands)(unaudited) | |||||||||||||||||
Chemed | |||||||||||||||||
VITAS | Roto-Rooter | Corporate | Consolidated | ||||||||||||||
2017 |
|||||||||||||||||
Service revenues and sales | $ | 282,316 | $ | 123,548 | $ | - | $ | 405,864 | |||||||||
Cost of services provided and goods sold | 221,678 | 63,462 | - | 285,140 | |||||||||||||
Selling, general and administrative expenses (a) | 24,294 | 33,460 | 11,704 | 69,458 | |||||||||||||
Depreciation | 4,778 | 3,984 | 131 | 8,893 | |||||||||||||
Amortization | 14 | 32 | - | 46 | |||||||||||||
Other operating expenses | 873 | - | - | 873 | |||||||||||||
Total costs and expenses | 251,637 | 100,938 | 11,835 | 364,410 | |||||||||||||
Income/(loss) from operations | 30,679 | 22,610 | (11,835 | ) | 41,454 | ||||||||||||
Interest expense | (55 | ) | (99 | ) | (841 | ) | (995 | ) | |||||||||
Intercompany interest income/(expense) | 2,702 | 1,310 | (4,012 | ) | - | ||||||||||||
Other income/(expense)—net | (80 | ) | (72 | ) | 2,615 | 2,463 | |||||||||||
Income/(loss) before income taxes | 33,246 | 23,749 | (14,073 | ) | 42,922 | ||||||||||||
Income taxes (a) | (12,649 | ) | (9,125 | ) | 8,696 | (13,078 | ) | ||||||||||
Net income/(loss) | $ | 20,597 | $ | 14,624 | $ | (5,377 | ) | $ | 29,844 | ||||||||
2016 |
|||||||||||||||||
Service revenues and sales | $ | 277,528 | $ | 112,861 | $ | - | $ | 390,389 | |||||||||
Cost of services provided and goods sold | 219,266 | 59,169 | - | 278,435 | |||||||||||||
Selling, general and administrative expenses (b) | 24,783 | 29,807 | 4,455 | 59,045 | |||||||||||||
Depreciation | 4,781 | 3,501 | 142 | 8,424 | |||||||||||||
Amortization | 14 | 78 | - | 92 | |||||||||||||
Total costs and expenses | 248,844 | 92,555 | 4,597 | 345,996 | |||||||||||||
Income/(loss) from operations | 28,684 | 20,306 | (4,597 | ) | 44,393 | ||||||||||||
Interest expense | (59 | ) | (93 | ) | (690 | ) | (842 | ) | |||||||||
Intercompany interest income/(expense) | 2,103 | 948 | (3,051 | ) | - | ||||||||||||
Other income/(expense)-net | 41 | 23 | (2,988 | ) | (2,924 | ) | |||||||||||
Income/(loss) before income taxes | 30,769 | 21,184 | (11,326 | ) | 40,627 | ||||||||||||
Income taxes (b) | (11,682 | ) | (8,164 | ) | 4,059 | (15,787 | ) | ||||||||||
Net income/(loss) | $ | 19,087 | $ | 13,020 | $ | (7,267 | ) | $ | 24,840 |
The "Footnotes to Financial Statements" are integral parts of this financial information.
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | ||||||||||||||||||||||
CONSOLIDATING SUMMARY OF EBITDA | ||||||||||||||||||||||
FOR THE THREE MONTHS ENDED MARCH 31, 2017 AND 2016 | ||||||||||||||||||||||
(in thousands)(unaudited) | ||||||||||||||||||||||
Chemed | ||||||||||||||||||||||
VITAS | Roto-Rooter | Corporate | Consolidated | |||||||||||||||||||
2017 | ||||||||||||||||||||||
Net income/(loss) | $ | 20,597 | $ | 14,624 | $ | (5,377 | ) | $ | 29,844 | |||||||||||||
Add/(deduct): | ||||||||||||||||||||||
Interest expense | 55 | 99 | 841 | 995 | ||||||||||||||||||
Income taxes | 12,649 | 9,125 | (8,696 | ) | 13,078 | |||||||||||||||||
Depreciation | 4,778 | 3,984 | 131 | 8,893 | ||||||||||||||||||
Amortization | 14 | 32 | - | 46 | ||||||||||||||||||
EBITDA | 38,093 | 27,864 | (13,101 | ) | 52,856 | |||||||||||||||||
Add/(deduct): | ||||||||||||||||||||||
Intercompany interest income/(expense) | (2,702 | ) | (1,310 | ) | 4,012 | - | ||||||||||||||||
Interest income | (70 | ) | (15 | ) | - | (85 | ) | |||||||||||||||
Expenses related to O.I.G. investigation | 2,150 | - | - | 2,150 | ||||||||||||||||||
Amortization of stock awards | 78 | 70 | 188 | 336 | ||||||||||||||||||
Program closure expenses | 873 | - | - | 873 | ||||||||||||||||||
Advertising cost adjustment (c) | - | (274 | ) | - | (274 | ) | ||||||||||||||||
Stock option expense | - | - | 3,001 | 3,001 | ||||||||||||||||||
Long-term incentive compensation | - | - | 961 | 961 | ||||||||||||||||||
Adjusted EBITDA | $ | 38,422 | $ | 26,335 | $ | (4,939 | ) | $ | 59,818 | |||||||||||||
2016 | ||||||||||||||||||||||
Net income/(loss) | $ | 19,087 | $ | 13,020 | $ | (7,267 | ) | $ | 24,840 | |||||||||||||
Add/(deduct): | ||||||||||||||||||||||
Interest expense | 59 | 93 | 690 | 842 | ||||||||||||||||||
Income taxes | 11,682 | 8,164 | (4,059 | ) | 15,787 | |||||||||||||||||
Depreciation | 4,781 | 3,501 | 142 | 8,424 | ||||||||||||||||||
Amortization | 14 | 78 | - | 92 | ||||||||||||||||||
EBITDA | 35,623 | 24,856 | (10,494 | ) | 49,985 | |||||||||||||||||
Add/(deduct): | ||||||||||||||||||||||
Intercompany interest income/(expense) | (2,103 | ) | (948 | ) | 3,051 | - | ||||||||||||||||
Interest income | (79 | ) | (17 | ) | (1 | ) | (97 | ) | ||||||||||||||
Expenses related to O.I.G. investigation | 2,336 | - | - | 2,336 | ||||||||||||||||||
Amortization of stock awards | 131 | 81 | 327 | 539 | ||||||||||||||||||
Advertising cost adjustment (c) | - | (608 | ) | - | (608 | ) | ||||||||||||||||
Stock option expense | - | - | 2,563 | 2,563 | ||||||||||||||||||
Long-term incentive compensation | - | - | (241 | ) | (241 | ) | ||||||||||||||||
Expenses related to securities litigation | - | - | 3 | 3 | ||||||||||||||||||
Adjusted EBITDA | $ | 35,908 | $ | 23,364 | $ | (4,792 | ) | $ | 54,480 |
The "Footnotes to Financial Statements" are integral parts of this financial information.
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | ||||||||||||
RECONCILIATION OF ADJUSTED NET INCOME | ||||||||||||
(in thousands, except per share data)(unaudited) | ||||||||||||
Three Months Ended March 31, | ||||||||||||
2017 | 2016 | |||||||||||
Net income as reported | $ | 29,844 | $ | 24,840 | ||||||||
Add after-tax cost of: | ||||||||||||
Excess tax benefits on stock compensation | (3,695 | ) | - | |||||||||
Stock option expense | 1,897 | 1,621 | ||||||||||
Expenses related to O.I.G. investigation | 1,328 | 1,443 | ||||||||||
Long-term incentive compensation | 608 | (152 | ) | |||||||||
Program closure expenses | 513 | - | ||||||||||
Expenses related to securities litigation | - | 2 | ||||||||||
Adjusted net income | $ | 30,495 | $ | 27,754 | ||||||||
Diluted Earnings Per Share As Reported | ||||||||||||
Net income | $ | 1.78 | $ | 1.45 | ||||||||
Average number of shares outstanding | 16,801 | 17,170 | ||||||||||
Adjusted Diluted Earnings Per Share | ||||||||||||
Adjusted net income | $ | 1.82 | $ | 1.62 | ||||||||
Average number of shares outstanding | 16,801 | 17,170 |
The "Footnotes to Financial Statements" are integral parts of this financial information.
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | |||||||||||||
OPERATING STATISTICS FOR VITAS SEGMENT | |||||||||||||
(unaudited) | |||||||||||||
Three Months Ended March 31, | |||||||||||||
OPERATING STATISTICS | 2017 | 2016 | |||||||||||
Net revenue ($000) (d) | |||||||||||||
Homecare | $ | 225,536 | $ | 214,850 | |||||||||
Inpatient | 23,923 | 25,517 | |||||||||||
Continuous care | 32,857 | 37,161 | |||||||||||
Total | $ | 282,316 | $ | 277,528 | |||||||||
Net revenue as a percent of total | |||||||||||||
before Medicare cap allowance | |||||||||||||
Homecare | 79.9 | % | 77.4 | % | |||||||||
Inpatient | 8.5 | 9.2 | |||||||||||
Continuous care | 11.6 | 13.4 | |||||||||||
Total | 100.0 | % | 100.0 | % | |||||||||
Average daily census ("ADC") (days) | |||||||||||||
Homecare | 12,287 | 11,681 | |||||||||||
Nursing home | 3,052 | 2,991 | |||||||||||
Routine homecare | 15,339 | 14,672 | |||||||||||
Inpatient | 378 | 421 | |||||||||||
Continuous care | 505 | 560 | |||||||||||
Total | 16,222 | 15,653 | |||||||||||
Total Admissions | 17,563 | 16,868 | |||||||||||
Total Discharges | 17,213 | 16,743 | |||||||||||
Average length of stay (days) | 88.7 | 83.7 | |||||||||||
Median length of stay (days) | 15.0 | 15.0 | |||||||||||
ADC by major diagnosis | |||||||||||||
Neurological | 19.7 | % | 22.1 | % | |||||||||
Cerebro | 34.4 | 31.2 | |||||||||||
Cancer | 15.1 | 15.3 | |||||||||||
Cardio | 16.6 | 17.3 | |||||||||||
Respiratory | 7.9 | 7.9 | |||||||||||
|
Other | 6.3 | 6.2 | ||||||||||
Total | 100.0 | % | 100.0 | % | |||||||||
Admissions by major diagnosis | |||||||||||||
Neurological | 10.9 | % | 11.3 | % | |||||||||
Cerebro | 22.1 | 20.9 | |||||||||||
Cancer | 29.5 | 30.5 | |||||||||||
Cardio | 15.1 | 15.5 | |||||||||||
Respiratory | 11.7 | 10.9 | |||||||||||
Other | 10.7 | 10.9 | |||||||||||
Total | 100.0 | % | 100.0 | % | |||||||||
Direct patient care margins (e) | |||||||||||||
Routine homecare | 51.3 | % | 52.1 | % | |||||||||
Inpatient | 5.9 | 5.7 | |||||||||||
Continuous care | 15.6 | 15.1 | |||||||||||
Homecare margin drivers (dollars per patient day) | |||||||||||||
Labor costs | $ | 58.64 | $ | 56.72 | |||||||||
Combined drug, home medical equipment and | |||||||||||||
medical supplies cost | 15.14 | 15.46 | |||||||||||
Inpatient margin drivers (dollars per patient day) | |||||||||||||
Labor costs | $ | 369.99 | $ | 338.73 | |||||||||
Continuous care margin drivers (dollars per patient day) | |||||||||||||
Labor costs | $ | 590.73 | $ | 599.38 | |||||||||
Bad debt expense as a percent of revenues | 1.2 | % | 1.3 | % | |||||||||
Accounts receivable -- | |||||||||||||
Days of revenue outstanding- excluding unapplied Medicare payments | 35.9 | 38.3 | |||||||||||
Days of revenue outstanding- including unapplied Medicare payments | 24.9 | 36.8 |
The "Footnotes to Financial Statements" are integral parts of this financial information.
CHEMED CORPORATION AND SUBSIDIARY COMPANIES | ||||||||||||||||||
FOOTNOTES TO FINANCIAL STATEMENTS | ||||||||||||||||||
FOR THE THREE MONTHS ENDED MARCH 31, 2017 AND 2016 | ||||||||||||||||||
(unaudited) | ||||||||||||||||||
(a) | Included in the results of operations for the three months ended March 31, 2017, are the following significant credits/(charges) | |||||||||||||||||
which may not be indicative of ongoing operations (in thousands): | ||||||||||||||||||
VITAS | Corporate | Total | ||||||||||||||||
Selling, general and administrative expenses | ||||||||||||||||||
Expenses related to O.I.G. investigation | $ | (2,150 | ) | $ | - | $ | (2,150 | ) | ||||||||||
Program closure expenses | (873 | ) | - | (873 | ) | |||||||||||||
Stock option expense | - | (3,001 | ) | (3,001 | ) | |||||||||||||
Long-term incentive compensation | - | (961 | ) | (961 | ) | |||||||||||||
Pretax impact on earnings | (3,023 | ) | (3,962 | ) | (6,985 | ) | ||||||||||||
Excess tax benefits on stock compensation | - | 3,695 | 3,695 | |||||||||||||||
Income tax benefit/(charge) on the above | 1,182 | 1,457 | 2,639 | |||||||||||||||
After-tax impact on earnings | $ | (1,841 | ) | $ | 1,190 | $ | (651 | ) | ||||||||||
(b) | Included in the results of operations for the three months ended March 31, 2016, are the following significant credits/(charges) | |||||||||||||||||
which may not be indicative of ongoing operations (in thousands): | ||||||||||||||||||
VITAS | Corporate | Total | ||||||||||||||||
Selling, general and administrative expenses | ||||||||||||||||||
Expenses related to O.I.G. investigation | $ | (2,336 | ) | $ | - | $ | (2,336 | ) | ||||||||||
Stock option expense | - | (2,563 | ) | (2,563 | ) | |||||||||||||
Long-term incentive compensation | - | 241 | 241 | |||||||||||||||
Expenses related to securities litigation | - | (3 | ) | (3 | ) | |||||||||||||
Pretax impact on earnings | (2,336 | ) | (2,325 | ) | (4,661 | ) | ||||||||||||
Income tax benefit/(charge) on the above | 893 | 854 | 1,747 | |||||||||||||||
After-tax impact on earnings | $ | (1,443 | ) | $ | (1,471 | ) | $ | (2,914 | ) |
(c) | Under Generally Accepted Accounting Principles ("GAAP"), the Roto-Rooter segment expenses all advertising, including the cost of |
telephone directories, immediately upon the initial release of the advertising. Telephone directories are generally in circulation 12 | |
months. If a directory is in circulation for a time period greater or less than 12 months, the publisher adjusts the directory billing for the | |
change in billing period. The timing of when a telephone directory is published can and does fluctuate significantly on a quarterly basis. | |
This "direct expensing" results in significant fluctuations in quarterly advertising expense. In the first quarters of 2017 and 2016, | |
GAAP advertising expense for Roto-Rooter totaled $6,906,000 and $6,283,000, respectively. If the expense of the telephone | |
directories were spread over the periods they are in circulation, advertising expense for the first quarters of 2017 and 2016 would | |
total $7,180,000 and $6,891,000, respectively. | |
(d) | VITAS has eight large (greater than 450 ADC), 18 medium (greater than 200 but less than 450 ADC) and 19 small (less than 200 ADC) hospice |
programs. Of VITAS' 31 unique Medicare provider numbers, 28 provider numbers have a Medicare cap cushion of 10% or greater during | |
the current Medicare cap year, two provider numbers have a Medicare cap cushion between 5% and 10% and one provider number has a | |
Medicare cap cushion between 0% and 5% | |
(e) | Amounts exclude indirect patient care and administrative costs, as well as Medicare Cap billing limitation. |
View source version on businesswire.com: http://www.businesswire.com/news/home/20170426005991/en/
Source:
Chemed Corporation
David P. Williams, 513-762-6901